-
1.发明授权Method for preparing a biodegradable polymer microsphere containing a glucose-regulating peptide 失效制备含有葡萄糖调节肽的可生物降解聚合物微球的方法公开(公告)号：US08282990B2
公开(公告)日：2012-10-09
申请号：US12595434
申请日：2008-04-18
申请人： Hyun Hee Kwak , Ghun II Lee , Yong Man Park , Mi Kyung Son , Hi Chang Yang , Tae Hyoung Kim , Yoon Ji Kim , Byong Moon Kim , Sung Hee Lee , Soo Hyung Kang , Moohi Yoo
发明人： Hyun Hee Kwak , Ghun II Lee , Yong Man Park , Mi Kyung Son , Hi Chang Yang , Tae Hyoung Kim , Yoon Ji Kim , Byong Moon Kim , Sung Hee Lee , Soo Hyung Kang , Moohi Yoo
CPC分类号： A61K9/1647 , A61K38/26 , Y02A50/465
摘要： Disclosed are biodegradable microspheres, capable of releasing a glucose-regulating peptide in a controlled manner, comprising a biodegradable polymer carrier with the glucose -regulating peptide encapsulated therein, and methods for the preparation thereof. In addition to ensuring high encapsulation efficiency and high stability of the encapsulated drug, the microspheres shows neither an initial burst effect nor incomplete release and allows the zero -order release of drugs over a prolonged period of time, thus improving the therapeutic effect of the drug.
摘要翻译： 公开了能够以受控方式释放葡萄糖调节肽的生物可降解微球，其包含其中包封有葡萄糖调节肽的生物可降解聚合物载体及其制备方法。 除了确保包封药物的高封装效率和高稳定性之外，微球体既不显示初始爆发效应也不显示不完全释放，并允许药物在一段较长时间内零次释放，从而改善药物的治疗效果 。
-
2.发明申请BIODEGRADABLE MICROSPHERE COMPOSITION SUITABLE FOR THE CONTROLLED RELEASE OF GLUCOSE CONTROLLING PEPTIDE AND FORMULATION THEREOF 失效生物可降解微生物组合物，适用于控制葡萄糖控制肽及其制剂的释放公开(公告)号：US20100129459A1
公开(公告)日：2010-05-27
申请号：US12595434
申请日：2008-04-18
申请人： Hyun Hee Kwak , Ghun Lee, II , Yong Man Park , Mi Kyung Son , Hi Chang Yang , Tae Hyoung Kim , Yoon Ji Kim , Byong Moon Kim , Sung Hee Lee , Soo Hyung Kang , Moohi Yoo
发明人： Hyun Hee Kwak , Ghun Lee, II , Yong Man Park , Mi Kyung Son , Hi Chang Yang , Tae Hyoung Kim , Yoon Ji Kim , Byong Moon Kim , Sung Hee Lee , Soo Hyung Kang , Moohi Yoo
CPC分类号： A61K9/1647 , A61K38/26 , Y02A50/465
摘要： Disclosed are biodegradable microspheres, capable of releasing a glucose-regulating peptide in a controlled manner, comprising a biodegradable polymer carrier with the glucose-regulating peptide encapsulated therein, and methods for the preparation thereof. In addition to ensuring high encapsulation efficiency and high stability of the encapsulated drug, the microspheres shows neither an initial burst effect nor incomplete release and allows the zero-order release of drugs over a prolonged period of time, thus improving the therapeutic effect of the drug.
摘要翻译： 公开了能够以受控方式释放葡萄糖调节肽的生物可降解微球，其包含其中包含葡萄糖调节肽的生物可降解聚合物载体及其制备方法。 除了确保包封药物的高封装效率和高稳定性之外，微球体既不显示初始爆发效应也不显示不完全释放，并允许药物在较长时间内零次释放，从而改善药物的治疗效果 。
-
3.发明申请Agent Comprising Fgf2 as an Effective Ingredient For Treatment or Prevention of Asthma and Chronic Obstructive Pulmonary Disease 有权包含Fgf2作为治疗或预防哮喘和慢性阻塞性肺疾病的有效成分的药剂公开(公告)号：US20080172751A1
公开(公告)日：2008-07-17
申请号：US11568896
申请日：2005-05-12
申请人： Yoon-Keun Kim , Soo Hyung Kang , Byong Moon Kim , Miwon Son
发明人： Yoon-Keun Kim , Soo Hyung Kang , Byong Moon Kim , Miwon Son
IPC分类号： A01K67/00 , A61K38/18 , A61P11/06 , A61K31/713
CPC分类号： A01K67/0275 , A01K2207/05 , A01K2207/10 , A01K2217/07 , A01K2217/203 , A01K2227/105 , A01K2267/0368 , A61K38/1825 , C07K14/52 , C07K14/5437 , C07K14/57 , C12N15/8509
摘要： The present invention relates an agent comprising FGF2 (Fibroblast Growth Factor-2 or basic Fibroblast Growth Factor(bFGF)) as an effective ingredient for treatment or prevention of Asthma and Chronic Obstructive Pulmonary Disease(COPD). Also, The present invention relates Th1 asthma and COPD mouse animal model induced by Ovalbumin and double strand RNA. The therapeutic agent comprising FGF2 of the present invention can be used for treatment or prevention for airway fibrosis, airway inflammation, airway hyperresponsiveness, airway remodeling, asthma and COPD. Also, Th1 asthma and COPD mice animal model induced by Ovalbumin and double strand RNA can be used for development of therapeutic agent for asthma and COPD.
摘要翻译： 本发明涉及包含FGF2（成纤维细胞生长因子-2或碱性成纤维细胞生长因子（bFGF））作为治疗或预防哮喘和慢性阻塞性肺疾病（COPD）的有效成分的药剂。 此外，本发明涉及由卵白蛋白和双链RNA诱导的Th1哮喘和COPD小鼠动物模型。 包含本发明的FGF2的治疗剂可用于治疗或预防气道纤维化，气道炎症，气道高反应性，气道重塑，哮喘和COPD。 此外，Th1哮喘和COPD小鼠由卵白蛋白和双链RNA诱导的动物模型可用于开发哮喘和COPD治疗剂。
-
4.发明授权Method for treating asthma and chronic obstructive pulmonary disease (COPD) comprising administering FGF2 有权治疗哮喘和慢性阻塞性肺疾病（COPD）的方法，包括给予FGF2公开(公告)号：US08030274B2
公开(公告)日：2011-10-04
申请号：US11568896
申请日：2005-05-12
申请人： Yoon-Keum Kim , Soo Hyung Kang , Byong Moon Kim , Miwon Son
发明人： Yoon-Keum Kim , Soo Hyung Kang , Byong Moon Kim , Miwon Son
CPC分类号： A01K67/0275 , A01K2207/05 , A01K2207/10 , A01K2217/07 , A01K2217/203 , A01K2227/105 , A01K2267/0368 , A61K38/1825 , C07K14/52 , C07K14/5437 , C07K14/57 , C12N15/8509
摘要： The present invention relates an agent comprising FGF2 (Fibroblast Growth Factor-2 or basic Fibroblast Growth Factor (bFGF)) as an effective ingredient for treatment or prevention of Asthma and Chronic Obstructive Pulmonary Disease (COPD). Also, The present invention relates Th1 asthma and COPD mouse animal model induced by Ovalbumin and double strand RNA. The therapeutic agent comprising FGF2 of the present invention can be used for treatment or prevention for airway fibrosis, airway inflammation, airway hyperresponsiveness, airway remodeling, asthma and COPD. Also, Th1 asthma and COPD mice animal model induced by Ovalbumin and double strand RNA can be used for development of therapeutic agent for asthma and COPD.
摘要翻译： 本发明涉及包含FGF2（成纤维细胞生长因子-2或碱性成纤维细胞生长因子（bFGF））作为治疗或预防哮喘和慢性阻塞性肺疾病（COPD）的有效成分的药剂。 此外，本发明涉及由卵白蛋白和双链RNA诱导的Th1哮喘和COPD小鼠动物模型。 包含本发明的FGF2的治疗剂可用于治疗或预防气道纤维化，气道炎症，气道高反应性，气道重塑，哮喘和COPD。 此外，Th1哮喘和COPD小鼠由卵白蛋白和双链RNA诱导的动物模型可用于开发哮喘和COPD治疗剂。
-
-
-
搜索结果
4 条记录 (耗时 0.044 秒)
